Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Grbavac
Phone: 346.238.4456
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of th ... Read more >
Status: Open Not Enrolling
Investigator: Terry Clyburn
Study Coordinator:
Phone:
This study is designed to observe the long term clinical outcomes of patient-specific knee arthroplasty in patients with osteoarthritis. ... Read more >
Status: Open Not Enrolling
Investigator: Jason Thonhoff
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >
Status: Open Not Enrolling
Investigator: Sheetal Shroff
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG). ... Read more >
Status: Enrolling
Investigator: Tetsuo Ashizawa
Study Coordinator: Valerie Flores
Phone: 713.363.9803
The investigators plan to fill the gap between the current state of clinical trial readiness and the optimal one for SCA1 and SCA3, which are fatal rare diseases with no treatments. Through US-European collaborations, the investigators will esta ... Read more >
Status: Open Not Enrolling
Investigator: Lisa Kopas
Study Coordinator: Brooke Shope
Phone: 713.441.3248
The purpose of this research is to study a medical device that is designed to produce lung volume reduction. This device is called the PulmonX Endobronchial Valve (EBV). It has not been approved by the Food and Drug Administration (FDA) and is c ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Anjana Singh
Phone: 713.441.9120
Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Anjana Singh
Phone: 713.441.9120
The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >
Status: Open Not Enrolling
Investigator: Ericka Greene
Study Coordinator: Aramide Balogun
Phone: 713.441.6947
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293] ... Read more >
